# Nuclide record advancell (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/advancell/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "advancell" ;
  schema:name "AdvanCell"@en ;
  schema:alternateName "AdvanCell Isotopes"@en ;
  schema:description "An Australian biotech building its own supply of the rare radioactive metal lead-212 so it can make alpha-particle cancer therapies, starting with one for prostate cancer."@en ;
  schema:url <https://nuclide.cc/companies/advancell/>, <https://www.advancell.com.au> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.advancell.com.au/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure/>, <https://www.advancell.com.au/>, <https://www.bioxconomy.com/investment/advancell-lands-315m-to-solve-radiopharmaceutical-industry-s-biggest-constraint->, <https://brandoncapital.vc/portfolio/advancell/> ;
  nuclide:status "active" ;
  nuclide:tag "lead-212", "targeted alpha therapy", "prostate cancer" ;
  schema:addressCountry "AU" ;
  nuclide:related <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/actinium-225-supply/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/pb-212/>, <https://nuclide.cc/isotopes/ra-224/> .